STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Clinical trials for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests Double-Drug attack on tough skin cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug combination for advanced melanoma that has spread or cannot be surgically removed. It combines pembrolizumab, an immunotherapy drug, with ibrutinib, a drug that may block cancer cell growth. The goal is to s…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New pill tested as last hope for Tough-to-Treat skin cancer
Disease control OngoingThis study is testing whether a pill called ibrutinib can help control advanced skin melanoma that has continued to grow despite standard immunotherapies and other targeted drugs. It involves 18 patients with stage IV melanoma who take the pill daily. The main goal is to see if t…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:18 UTC
-
New drug trial aims to extend life for advanced melanoma patients
Disease control OngoingThis study is testing an experimental drug called dinaciclib in people with stage IV melanoma that has spread. The main goal is to see if the treatment helps patients live at least one year longer. Researchers will also monitor how well it controls the cancer's growth and what si…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Boosting the Body's army: can a second drug help immune therapy fight deadly melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Major cancer trial tests new immune therapy to keep deadly skin cancer at bay
Disease control OngoingThis large study aimed to find the best treatment to prevent melanoma skin cancer from returning after it has been surgically removed. It compared a newer immune-boosting drug called ipilimumab against the standard treatment, interferon. Over 1,600 patients with high-risk melanom…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Three-Drug attack on Tough-to-Treat skin cancer
Disease control OngoingThis study is testing two different combinations of three drugs to see if they are safe and effective for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has spread or cannot be removed by surgery. The goal is to control the cancer by using an…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test malaria drug combo against tough cancers
Disease control OngoingThis early-stage trial is testing whether combining an experimental cancer drug called MK-2206 with the malaria drug hydroxychloroquine is safe for people with advanced solid tumors, melanoma, kidney, or prostate cancer. The main goal is to find the highest dose patients can tole…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test new drug duo in fight against tough tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new drug duo to starve and stop tough cancers
Disease control OngoingThis early-stage study is testing a combination of two oral drugs, cediranib and selumetinib, in patients with advanced solid tumors that cannot be removed by surgery and have no standard treatment options. The main goals are to find the safest dose and understand the side effect…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Major cancer trial tests if adding a third drug makes powerful melanoma treatment better and safer
Disease control OngoingThis study is for adults with advanced melanoma that cannot be removed by surgery. It compares two immunotherapy combinations to see which helps patients live longer and has fewer severe side effects. One group gets two standard immunotherapy drugs, while the other gets those sam…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Two-Drug combo tested in fight against advanced skin cancer
Disease control OngoingThis study tested whether adding high-dose interferon to the immunotherapy drug ipilimumab helps control advanced melanoma better than ipilimumab alone. It also compared two different doses of ipilimumab. The trial involved 88 adults with stage III or IV melanoma that couldn't be…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Could drug breaks work just as well for fighting advanced skin cancer?
Disease control OngoingThis study is testing whether taking planned breaks from two targeted cancer drugs (dabrafenib and trametinib) is as effective as taking them continuously for people with advanced melanoma that has a specific genetic change (BRAF mutation). It aims to see if the 'on-and-off' sche…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:04 UTC
-
Scientists supercharge Patients' own cells to battle deadly skin cancer
Disease control OngoingThis early-stage study is testing the safety of a new personalized treatment for advanced melanoma. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, and then infuse them back into the body. The goal is to see if th…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New combo therapy fights back when melanoma outsmarts standard treatment
Disease control OngoingThis study is testing whether a two-part immunotherapy can help patients with advanced melanoma whose cancer has continued to grow despite standard immune-based treatments. It combines a modified virus injected directly into tumors (T-VEC) with an intravenous drug (pembrolizumab)…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 18:34 UTC
-
Doctors test inhaled cancer treatment to target lung tumors
Disease control OngoingThis early-stage study is testing an inhaled form of an immune-boosting drug (aldesleukin) for people whose cancer has spread to their lungs. The main goals are to find a safe dose and see if the treatment causes side effects. Researchers also want to learn if inhaling the drug d…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC